Jun. 26, 2019
Marrone Bio Innovations Inc. (NASDAQ:MBII) (MBI), a leading developer of biological crop protection and plant health solutions, has received a notice of allowance from the U.S. Patent and Trademark Office for key claims covering the composition and method of manufacturing for Grandevo WDG, an MBI developed microbial-based bioinsecticide.
A Notice of Allowance is a document sent to a patent applicant from the United States Patent and Trademark Office after a patent examiner has decided to issue the requested patent.
Pam Marrone, Founder and CEO of Marrone Bio Innovations, said that all allowed key claims, notably to the formulation claims surrounding Grandevo WDG would protect both the composition and method of manufacturing, fortifying their already robust patent position around this bioinsecticide product. "We look forward to continued revenue growth of our Grandevo product line, generating long-term value for our shareholders."
MBI holds more than 400 issued and pending patents, and has brought six EPA-registered biological product lines and one biostimulant to market – more than any other agricultural inputs company in that time.
Grandevo WDG bioinsecticide/miticide is derived from non-living bacteria that effectively controls a wide variety of chewing and sucking insects and mites, on a wide assortment of crops, from the unique action of multiple compounds through repellency, ingestion and reduction of pest fertility. In an integrated pest management (IPM) program, Grandevo WDG offers multiple modes of action that can significantly benefit producers trying to reduce the risk of pest resistance.
Grandevo WDG is exempt from the requirement of tolerances and therefore can be sprayed right up to harvest without creating concerns for exported produce or produce that must meet strict residue requirements of the food marketing chain.